 |
市场调查报告书
商品编码
1890921
噬菌体疗法市场按产品、目标病原体、疾病适应症、给药途径、最终用户和地区划分Phage Therapy Market, By Product, By Target Pathogen, By Disease Indication, By Route of Administration, By End User, By Geography |
||||||
预计到 2025 年，噬菌体疗法市值将达到 13.4 亿美元，到 2032 年将达到 20.3 亿美元，2025 年至 2032 年的复合年增长率为 6.1%。
| 报告内容 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2024 | 2025年市场规模： | 13.4亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2025年至2032年 |
| 预测期（2025-2032年）复合年增长率： | 6.10% | 2032 年的预测值： | 20.3亿美元 |
全球噬菌体疗法市场代表了一种利用噬菌体（一种天然存在的病毒，能够特异性靶向并摧毁致病菌）来治疗细菌感染疾病的创新方法。随着抗生素抗药性在全球范围内持续蔓延，噬菌体疗法正成为一种极具前景的治疗方法选择，它能够提供精准医疗手段，以应对对传统抗生素抗药性的多重抗药性细菌感染疾病。这种创新疗法利用了噬菌体与细菌之间天然的捕食者-猎物关係，驾驭这些微小的生物体选择性地清除有害菌株，同时保护有益菌群。
该市场涵盖多种基于噬菌体的产品，包括个人化噬菌体混合物、标准化治疗製剂以及用于细菌鑑定和药敏试验的诊断工具。噬菌体疗法的应用遍及多个医学领域，包括治疗慢性伤口感染疾病、呼吸道感染疾病、尿道感染和胃肠道疾病。监管机构对噬菌体疗法潜力的日益认可，以及研发投入的不断增加，预计将推动该市场显着成长。医疗机构和製药公司正积极探索噬菌体疗法作为应对全球抗菌素抗药性危机的有效解决方案，推动生产流程、品管标准和临床试验调查方法的创新，以建立稳健的治疗通讯协定。
市场动态
全球噬菌体疗法市场正经历着强劲的成长势头，这主要得益于多种因素的推动。其中最突出的因素是日益严峻的全球抗生素抗药性危机，这场危机使得传统治疗方法对多重抗药性细菌感染疾病束手无策。世界卫生组织（WHO）已将抗菌素抗药性列为全球十大公共卫生威胁之一，这加速了对替代治疗方法的研究投资和监管支持，并将噬菌体疗法定位为关键解决方案。医院感染、慢性伤口和细菌生物膜相关疾病的增加进一步推动了市场需求，因为医疗机构正在寻求副作用较少的标靶治疗。医疗专业人员和患者对个人化医疗方法的认识不断提高，加上成功的临床案例研究证明了噬菌体疗法的有效性，这些因素持续推动市场应用。然而，该市场也面临许多限制因素，例如复杂的法规结构缺乏噬菌体疗法的标准化核准途径，导致研发週期长、成本高昂。
噬菌体稳定性、品管和大规模生产流程等方面的製造挑战，为商业化带来了额外的障碍。有限的临床试验数据以及需要对多种细菌菌株进行广泛的安全性和有效性研究，限制了市场的快速扩张。此外，高昂的研发成本、复杂的智慧财产权问题以及对专业储存和分销基础设施的需求，也构成了中小企业进入该市场的障碍。然而，製药公司和生物技术公司之间的策略联盟、政府资助的抗菌素抗药性研究计画以及在兽医学和农业领域不断扩展的应用，都蕴藏着巨大的机会。噬菌体库的出现、合成生物学技术的进步使得工程化噬菌体成为可能，以及噬菌体与传统抗生素联合治疗的日益普及，都为市场参与企业提供了盈利的成长路径。
本次调查的主要特点
- 本报告对全球噬菌体疗法市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）内的市场规模（十亿美元）和復合年增长率（%）。
- 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数介绍了全球噬菌体疗法市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球噬菌体疗法市场报告的目标受众包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员可以透过各种用于分析全球噬菌体疗法市场的策略矩阵轻鬆做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章 市场动态、监理及趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2020-2032年全球噬菌体疗法市场（依产品划分）
- 单核细胞疗法
- 噬菌体鸡尾酒
- 基因工程噬菌体
- 噬菌体衍生酶（例如，内溶素）
- 组合产品（噬菌体+抗生素或佐剂）
5. 2020-2032年全球噬菌体疗法市场（以标靶病原体划分）
- 革兰氏阴性菌
- 革兰氏阳性菌
6. 2020-2032年全球噬菌体疗法市场（依疾病适应症划分）
- 尿道感染（UTI）
- 皮肤和伤口感染疾病
- 骨骼和关节/植入相关感染疾病
- 呼吸道感染疾病（包括囊肿纤维化）
- 胃肠道感染疾病
- 血液感染疾病/败血症
- 生物膜相关慢性感染疾病
- 其他疾病适应症
7. 2020-2032年全球噬菌体疗法市场（依给药途径划分）
- 口服
- 局部/皮肤给药
- 注射剂/静脉注射（IV/IM）
- 吸入/雾化器
- 局部注射（例如，膀胱内、伤口腔内）
- 其他给药途径
8. 2020-2032年全球噬菌体疗法市场（依最终用户划分）
- 医院和专科诊所
- 研究机构和学术中心
- 门诊护理/门诊诊所
- 其他（兽医诊所）
9. 2020-2032年全球噬菌体疗法市场（按地区划分）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十章 竞争格局
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGOTAC Therapeutics（or Fagoterapia）
- Evolution Biotechnologies Inc
- Tol ka AI Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
第十一章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十二章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Phage Therapy Market is estimated to be valued at USD 1.34 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.10% | 2032 Value Projection: | USD 2.03 Bn |
The global phage therapy market represents a revolutionary approach to combating bacterial infections through the therapeutic application of bacteriophages, naturally occurring viruses that specifically target and destroy bacterial pathogens. As antibiotic resistance continues to escalate worldwide, phage therapy has emerged as a promising alternative treatment modality, offering precision medicine capabilities that can address multidrug-resistant bacterial infections where conventional antibiotics have failed. This innovative therapeutic approach leverages the natural predator-prey relationship between bacteriophages and bacteria, utilizing these microscopic entities to selectively eliminate harmful bacterial strains while preserving beneficial microbiota.
The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.
Market Dynamics
The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.
Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.
Key Features of the Study
- This report provides in-depth analysis of the global phage therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global phage therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Armata Pharmaceuticals Inc, BiomX Inc, Pherecydes Pharma SAS, Intralytix Inc, Locus Biosciences Inc, Nextbiotics Ltd, Proteon Pharmaceuticals SA, iNtRON Biotechnology Co Ltd, Micreos BV, Eligo Bioscience SA, FAGOTAC Therapeutics (or Fagoterapia), Evolution Biotechnologies Inc, Tol ka AI Therapeutics Inc, PrecisionPhage Oy, and Obulytix Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global phage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phage therapy market
Market Segmentation
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Monophage therapy
- Phage cocktails
- Engineered/recombinant phages
- Phage derived enzymes (e.g., endolysins)
- Combination products (phage + antibiotic or adjunct)
- Target Pathogen Insights (Revenue, USD Bn, 2020 - 2032)
- Gram negative bacteria
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram-negative bacteria
- Gram positive bacteria
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram-positive bacteria
- Mixed/other pathogens
- Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Urinary tract infections (UTIs)
- Skin and wound infections
- Bone and joint/implant associated infections
- Respiratory tract infections (including cystic fibrosis)
- Gastrointestinal infections
- Bloodstream/sepsis infections
- Biofilm related chronic infections
- Other indications
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Topical/dermal
- Injectable/intravenous (IV/IM)
- Inhalation/nebulized
- Local instillation (e.g., bladder, wound cavity)
- Other routes
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and specialty clinics
- Research institutes and academic centers
- Ambulatory care/outpatient clinics
- Others (Veterinary clinics)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGOTAC Therapeutics (or Fagoterapia)
- Evolution Biotechnologies Inc
- Tol ka AI Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Phage Therapy Market, By Product
- Global Phage Therapy Market, By Target Pathogen
- Global Phage Therapy Market, By Disease Indication
- Global Phage Therapy Market, By Route of Administration
- Global Phage Therapy Market, By End User
- Global Phage Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Phage Therapy Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Monophage therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage cocktails
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Engineered/recombinant phages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage derived enzymes (e.g., endolysins)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination products (phage + antibiotic or adjunct)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Phage Therapy Market, By Target Pathogen, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gram negative bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram-negative bacteria
- Gram positive bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram-positive bacteria
- Mixed/other pathogens
6. Global Phage Therapy Market, By Disease Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Urinary tract infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Skin and wound infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bone and joint/implant associated infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Respiratory tract infections (including cystic fibrosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastrointestinal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bloodstream/sepsis infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biofilm related chronic infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Phage Therapy Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical/dermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable/intravenous (IV/IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation/nebulized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Local instillation (e.g., bladder, wound cavity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Phage Therapy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and specialty clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research institutes and academic centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory care/outpatient clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Veterinary clinics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Phage Therapy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Armata Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BiomX Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pherecydes Pharma SAS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intralytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Locus Biosciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nextbiotics Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Proteon Pharmaceuticals SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- iNtRON Biotechnology Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Micreos BV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eligo Bioscience SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FAGOTAC Therapeutics (or Fagoterapia)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evolution Biotechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tol ka AI Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PrecisionPhage Oy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Obulytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
